Showing 81-90 of 119 results for "".
- Phase 3 Study Finds Twice-Weekly Enstilar Foam Safe and Effective for Long-Term Maintenance Treatment of Plaque Psoriasishttps://practicaldermatology.com/news/phase-3-study-finds-twice-weekly-enstilar-foam-safe-and-effective-for-long-term-maintenance-treatment-of-plaque-psoriasis/2460427/LEO Pharma A/S presented results from the Phase 3 PSO-LONG clinical tria, which compared the efficacy and safety of twice-weekly Enstilar (calcipotriene and betamethasone dipropionate) Foam versus foam vehicle for long-term (52-week) maintenance treatment for adult patients with plaque psoriasis. R…
- Further Evidence of Long-term Use and Cost-effectiveness of Ilumya for Psoriasis Presented at Virtual AADhttps://practicaldermatology.com/news/further-evidence-of-long-term-use-and-cost-effectiveness-of-ilumya-for-psoriasis-presented-at-virtual-aad/2460425/Sun Pharmaceutical Industries Ltd. presented further evidence of the long-term use and cost-effectiveness of tildrakizumab-asmn (Ilumya) in moderate to severe plaque psoriasis at the American Academy of Dermatology (AAD) Virtual Meeting Experience 2020. Long-term analyses of the reSURFACE 1 and 2 …
- LEO Pharma Enters License Agreement with Oneness Biotech, Microbio Shanghai for Atopic Dermatitis and Asthma Drug Candidatehttps://practicaldermatology.com/news/leo-pharma-enters-license-agreement-with-oneness-biotech-microbio-shanghai-for-atopic-dermatitis-and-asthma-drug-candidate/2460353/LEO Pharma A/S has signed a worldwide exclusive licensing agreement with Oneness Biotech of Taiwan and Microbio Shanghai of China, covering the development and commercialization of the novel Atopic Dermatitis (AD) and Allergic Asthma drug candidate, FB825. FB825 is a first-in-class drug candidate …
- UCB’s Bimekizumab Performs Well in Phase 3 Psoriasis Studyhttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-phase-3-psoriasis-study/2460186/UCB’s bimekizumab, an IL-17A and IL-17F inhibitor, bested placebo and Stelara (ustekinumab) when it came to clearing the skin of patients with moderate-to-severe chronic plaque psoriasis and improving their symptoms, the company reports. BE VIVID is the first of three Phase 3 studies evaluating th…
- L'Oréal USA Announces Winners Of 2019 Women In Digital Next Generation Awardshttps://practicaldermatology.com/news/loreal-usa-announces-winners-of-2019-women-in-digital-next-generation-awards/2460152/L'Oréal USA announced the winners of the 2019 Women in Digital NEXT Generation Awards. The three winners, each of whom will receive $25,000 in grant funding, include Mandi Nyambi and Lanya Olmsted, the co-founders of Baalm, an online community for beauty; Lisha Li, the founder of Rosebud AI, a tec…
- Immunotherapy Appears Better Than Chemotherapy for Aggressive Merkle Cell Carcinomahttps://practicaldermatology.com/news/immunotherapy-appears-better-than-chemotherapy-for-aggressive-merkle-cell-carcinoma/2459909/First-line therapy with Pembrolizumab may produce better responses and result in longer survival in Merkel cell carcinoma than conventional chemotherapy. The study, co-led by Suzanne Topalian, M.D., associate director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins …
- LEO Pharma Focuses on Translational Medicine, Appoints Dr. Adam B. Raff as Director & Medical Advisorhttps://practicaldermatology.com/news/leo-pharma-strengthens-focus-on-translational-medicine-with-appointment-of-dr-adam-b-raff-as-director-medical-advisor/2459942/LEO Pharma has appointed Adam B. Raff, MD, PhD as Director and Medical Advisor in Translational Medicine, effective January 28. Dr. Raff’s primary objective will be to support LEO Pharma’s ambitions to advance science within dermatology through translational medicine, the company says. Adam Raff i…
- “Christmas Berry” Plant Compound Could Fight Uveal Melanomahttps://practicaldermatology.com/news/christmas-berry-plant-compound-could-fight-uveal-melanoma/2459945/A compound extracted from the Christmas berry primrose plant may stops the growth of uveal melanoma, according to preliminary tests. With further testing, the discovery could lead to new therapeutic options for patients with uveal melanoma, report researches from the Sidney Kimmel Cancer Center (…
- Skin Cancer Foundation: Champions for Change Gala Raises $600,000https://practicaldermatology.com/news/skin-cancer-foundation-champions-for-change-gala-raises-600000/2457527/The Skin Cancer Foundation’s 22nd annual Gala raised $600,000 to support the organization’s educational campaigns, community programs, and research initiatives. More than 400 guests attended the event, including Skin Cancer Foundation donors, industry and physician allies, celebrity supporters and …
- Mind the Gap: Disparity Between Urban and Rural Derms Widenshttps://practicaldermatology.com/news/mind-the-gap-disparity-between-urban-and-rural-derms-widens/2457618/The gap between dermatologists in urban and rural areas is widening across the United States, according to a new study of county-level data from 1995 to 2013 in JAMA Dermatology. Specifically, dermatologist density increased by 21 percent from 3.02 per 100 000 people to 3.65 per 100 000 people fro…